Related Experiment Video
Updated: Dec 15, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.3K
Hepatoblastoma: current knowledge and promises from preclinical studies.
Diego F Calvisi1, Antonio Solinas2
1Institute of Pathology, University of Regensburg, Regensburg, Germany.
Translational Gastroenterology and Hepatology
|July 8, 2020
Summary
Survival rates for metastatic hepatoblastoma (HB) have improved significantly due to better risk stratification and treatment. New molecular insights are paving the way for targeted therapies for patients with poor prognoses.
Area of Science:
- Pediatric Oncology
- Molecular Pathology
- Cancer Genomics
Background:
- Metastatic hepatoblastoma (HB) survival has risen from 27% to 79% over 30 years.
- Improved outcomes are linked to risk stratification, chemotherapy, and surgery.
- Patients with poor prognoses still need more effective therapeutic strategies.
Purpose of the Study:
- To review the molecular pathology of hepatoblastoma.
- To identify driver genes and novel therapeutic targets.
- To discuss the role of in vivo models in understanding HB development and pre-clinical therapy evaluation.
Main Methods:
- Literature review of molecular pathology in hepatoblastoma.
- Analysis of driver genes in oncogenesis.
- Examination of in vivo models for disease mechanisms and therapeutic development.
Main Results:
- Significant advancements in understanding HB biology.
- Identification of key oncogenic pathways and potential therapeutic targets.
- Validation of in vivo models for pre-clinical research.
Conclusions:
- Molecular insights are crucial for advancing hepatoblastoma treatment.
- Targeted therapies based on molecular classification hold promise for poor-prognosis patients.
- In vivo models are essential for developing and testing novel treatment modalities.
